Intellipharmaceutics International Inc. (IPCI)
(Delayed Data from NSDQ)
$0.21 USD
0.00 (0.00%)
Updated Mar 20, 2019 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Intellipharmaceutics International Inc. [IPCI]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Looking ahead to 2019 for Oxycodone ER - Neutral
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
ValuEngine Detailed Valuation Report for IPCI
Provider: ValuEngine, Inc
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Continued Pipeline Progress; NASDAQ Listing Appeal Successful; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
ANDA Pipeline and Oxycodone ER Resubmission in Spotlight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Updated Extended-Release Oxycodone Timeline; Medical Need Remains Massive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Not Your Average Specialty Pharma Company; Initiating at Buy and $2.50 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
SMALL-CAP SQUAWK
Provider: JGR Capital Partners
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
We are initiating coverage on IPCI shares with a BUY rating and 2-3-year price target of $7.30 per share.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
The Downside of the 505(b)(2) Regulatory Path
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
IPCI Receives FDA Final Approval for Generic Glucophage
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
IPCI Announces Acceptance of Rexista? Filing
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: GRISEWOOD S
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
MORNING & MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
Company: Intellipharmaceutics International Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.